Market news

STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences: Morgan Stanley 24th Annual Global Healthcare ConferenceFireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ETNew York, NY H.C. Wainwright 28th Annual Global

Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Management attributed top-line growth to the expansion of its ADHD business, notably Jornay PM’s 41% year-over-year revenue increase and broader prescriber reach. CEO Vikram Karnani stressed that the integration of recently acquired Azstarys was completed ahead of the crucial back-to-school season, reinforcing the company’s strategy to diversif

Collegium Pharmaceutical (COLL) stock rises as the company annouces a $50M accelerated share repurchase agreement with Jefferies (JEF). Read more here.

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its

Motley Fool Press Release.

Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise. President and Chief Executive Officer Vikram Karnani said th

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Confer

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceuticals stocks fared in Q1, starting with Collegium Pharmaceutical (NASDAQ:COLL).

STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it will report second quarter 2026 financial results before the market opens on Thursday August 6, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information

Detailed price information for Collegium Pharma (COLL-Q) from The Globe and Mail including charting and trades.

New headquarters reflects Collegium's long-term vision and commitment to MassachusettsSTOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027. The decision reflects Collegium's continued evolution as a

BOSTON, July 20, 2026--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston’s Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and growt

Collegium Pharmaceutical Stock Update After Recent Trading Moves Collegium Pharmaceutical (COLL) has moved within a relatively tight range recently, with the stock down 0.5% over the last session but up in the past week and month. For investors tracking pain management specialists, Collegium Pharmaceutical’s roughly $1.2b market value, last close of $36.08, and 1-year total return of 15.6% set the stage for assessing whether current pricing aligns with its fundamentals. See our latest...

Collegium Pharmaceutical Stock Update After Recent Trading Moves Collegium Pharmaceutical (COLL) has moved within a relatively tight range recently, with the stock down 0.5% over the last session but up in the past week and month. For investors tracking pain management specialists, Collegium Pharmaceutical’s roughly $1.2b market value, last close of $36.08, and 1-year total return of 15.6% set the stage for assessing whether current pricing aligns with its fundamentals. See our latest...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.